TW200800966A - Beta-secretase modulators and methods of use - Google Patents
Beta-secretase modulators and methods of useInfo
- Publication number
- TW200800966A TW200800966A TW095143035A TW95143035A TW200800966A TW 200800966 A TW200800966 A TW 200800966A TW 095143035 A TW095143035 A TW 095143035A TW 95143035 A TW95143035 A TW 95143035A TW 200800966 A TW200800966 A TW 200800966A
- Authority
- TW
- Taiwan
- Prior art keywords
- compounds
- beta
- methods
- formula
- treatment
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73910805P | 2005-11-21 | 2005-11-21 | |
| US85482406P | 2006-10-27 | 2006-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200800966A true TW200800966A (en) | 2008-01-01 |
Family
ID=39708735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095143035A TW200800966A (en) | 2005-11-21 | 2006-11-21 | Beta-secretase modulators and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1971598A1 (zh) |
| JP (1) | JP5274258B2 (zh) |
| AR (1) | AR057985A1 (zh) |
| AU (1) | AU2006316620B2 (zh) |
| CA (1) | CA2629402C (zh) |
| PE (1) | PE20070645A1 (zh) |
| TW (1) | TW200800966A (zh) |
| WO (1) | WO2007061670A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200901991A (en) * | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| MX2009012608A (es) * | 2007-05-25 | 2009-12-07 | Amgen Inc | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. |
| US8946483B2 (en) | 2011-07-21 | 2015-02-03 | Ge Healthcare Limited | Precursor compounds and methods for making same |
| BR112014023384A8 (pt) * | 2012-03-20 | 2018-01-16 | R Artis Dean | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. |
| EP3170820B1 (en) | 2014-07-16 | 2019-02-20 | Japan Science and Technology Agency | Benzothiazole compound and medicine containing same |
| JP7413346B2 (ja) | 2019-03-06 | 2024-01-15 | 第一三共株式会社 | ピロロピラゾール誘導体 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| ATE314343T1 (de) | 2000-06-30 | 2006-01-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
| US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
| JP2005500319A (ja) | 2001-06-27 | 2005-01-06 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体 |
| KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
| BR0211118A (pt) | 2001-07-10 | 2004-10-26 | Elan Pharm Inc | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal |
| BR0211122A (pt) | 2001-07-10 | 2004-10-26 | Elan Pharm Inc | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal |
| MXPA04000334A (es) | 2001-07-11 | 2004-09-28 | Elan Pharm Inc | Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) substituidos. |
| MXPA04003245A (es) | 2001-10-04 | 2004-08-11 | Elan Pharm Inc | Hidroxipropilaminas. |
| BR0213138A (pt) | 2001-10-05 | 2004-08-24 | Elan Pharm Inc | Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto |
| MXPA04004079A (es) | 2001-10-29 | 2005-07-05 | Pharmacia & Upjohn Co Llc | Amidas hidroxi sustituidas para tratamiento de enfermedad de alzheimer. |
| RS50504A (sr) | 2001-11-08 | 2007-04-10 | Elan Pharmaceuticals Inc., | Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana |
| AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
| BR0214736A (pt) | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
| BR0306724A (pt) | 2002-01-04 | 2006-04-11 | Elan Pharm Inc | carboxamidas amino substituìdas para tratamento de doença de alzheimer |
| JP2005526714A (ja) | 2002-01-17 | 2005-09-08 | ニューロジェン・コーポレーション | カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体 |
| EP1515944A1 (en) | 2002-06-17 | 2005-03-23 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| US7115747B2 (en) | 2002-06-20 | 2006-10-03 | Pharmacia & Upjohn Company | Process for preparing oxazole intermediates |
| UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| US7362070B2 (en) | 2002-11-04 | 2008-04-22 | Hamilton Sundstrand Corporation | Electric motor control system including position determination and error correction |
| EP1562897B1 (en) | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| CA2507484A1 (en) * | 2002-11-27 | 2004-06-17 | Elan Pharmaceuticals, Inc. | Substituted ureas and carbamates |
| GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
| CA2512111A1 (en) | 2003-01-07 | 2004-07-29 | Merck And Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
| CA2518886A1 (en) | 2003-03-14 | 2004-09-23 | Merck Sharp & Dohme Limited | Method for treating mild cognitive impairment and for preventing or delaying alzheimer's disease |
| GB0305918D0 (en) | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
| BRPI0409627A (pt) | 2003-04-21 | 2006-04-25 | Elan Pharm Inc | 2-hidróxi-3-diaminoalcanos de fenacila |
| TW200512195A (en) | 2003-04-21 | 2005-04-01 | Elan Pharm Inc | Benzamide 2-hydroxy-3-diaminoalkanes |
| GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
| AU2003297826A1 (en) | 2003-06-16 | 2005-01-28 | Sunesis Pharmaceuticals, Inc | Aspartyl protease inhibitors |
| WO2005004802A2 (en) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| EP1643986A4 (en) | 2003-07-01 | 2009-04-08 | Merck & Co Inc | PHENYL ACARBOXYLATE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER |
| GB0317491D0 (en) * | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
| CA2553973A1 (en) * | 2004-01-21 | 2005-08-04 | Elan Pharmaceuticals, Inc. | Methods of treatment of amyloidosis using aspartyl-protease inihibitors |
| JP2007528403A (ja) * | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ，インコーポレイテッド | 二環式アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
| BRPI0509186A (pt) * | 2004-03-25 | 2007-08-28 | Elan Pharm Inc | 1,3-diaminopropanos 2-amino-e 2-tio-substituìdos |
-
2006
- 2006-11-13 AU AU2006316620A patent/AU2006316620B2/en not_active Ceased
- 2006-11-13 JP JP2008541258A patent/JP5274258B2/ja not_active Expired - Fee Related
- 2006-11-13 WO PCT/US2006/044058 patent/WO2007061670A1/en not_active Ceased
- 2006-11-13 EP EP06837478A patent/EP1971598A1/en not_active Withdrawn
- 2006-11-13 CA CA2629402A patent/CA2629402C/en not_active Expired - Fee Related
- 2006-11-20 PE PE2006001476A patent/PE20070645A1/es not_active Application Discontinuation
- 2006-11-21 TW TW095143035A patent/TW200800966A/zh unknown
- 2006-11-21 AR ARP060105083A patent/AR057985A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006316620A1 (en) | 2007-05-31 |
| CA2629402A1 (en) | 2007-05-31 |
| CA2629402C (en) | 2011-07-26 |
| AR057985A1 (es) | 2008-01-09 |
| AU2006316620B2 (en) | 2011-03-03 |
| EP1971598A1 (en) | 2008-09-24 |
| WO2007061670A1 (en) | 2007-05-31 |
| JP5274258B2 (ja) | 2013-08-28 |
| JP2009516684A (ja) | 2009-04-23 |
| PE20070645A1 (es) | 2007-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7925A (is) | Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm | |
| ZA201002115B (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| IL205002A0 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| MY149650A (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| HU0302788D0 (en) | New compounds | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| TW200738698A (en) | Organic compounds | |
| DE602005023782D1 (de) | Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit | |
| TW200700061A (en) | Organic compounds | |
| GB0328900D0 (en) | Novel compounds | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| TW200800966A (en) | Beta-secretase modulators and methods of use | |
| WO2007019078A3 (en) | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2007019111A3 (en) | Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TNSN06372A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| TN2010000373A1 (en) | The present invention provides oxadiazoanthracene |